EGFR and neoplasm: In addition, research by Dong et al., based on the analysis of the Cancer Genome Atlas cohort and the Guangdong Lung Cancer Institute cohort, showed that tumor mutation burden was significantly lower in patients with treatment-sensitive EGFR mutations than in patients with resistant or unknown EGFR mutations (28).